From a theoretical perspective, one can infer that despite the likely existence of high heterophilic
relations, indicated by the presence of thirteen groups in his network, no good friends are in the group with the highest density of relations, which reduces the increase of the existing social capital.
Throughout the dermis, small perivascular to interstitial heterophilic
and pleocellular infiltrates were present.
Human anti-species and heterophilic
antibody interference against reagent antibodies has been well documented, and other interfering antibodies have also been reported, (1-3) Misdiagnosis, subsequent inappropriate treatment, and adverse consequences for the patient can result from interferences yielding false results.
The presence of heterophilic
antibodies in high titers may lead to analytical errors in two-site immunoassays (2).
Histopathologically it was characterized by congestion, oedema, mononuclear and heterophilic
cell infiltration in the dermal layer.
Expression of CD6, a heterophilic
receptor for ALCAM expressed mainly in lymphocytes, has not been determined in the uterine endometrium or conceptuses in pigs so far, but it is possible that ALCAM may recruit and activate endometrial lymphocytes.
Some patients have heterophilic
antibodies that have the potential to raise or even lower the reported troponin level, giving a false positive or a false negative result.
antibody-blocking tube was used to adsorb heterophilic
antibodies prior to vitamin D assay.
TRU Block, a highly potent reagent, actively blocks the heterophilic
antibody (HA) interference in immunoassays, including Human Anti-Mouse Antibody (HAMA) interference.
growth under aerobic and anoxic conditions", Water Res.
antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration.
The 13 chapters on therapeutic drug monitoring discuss such issues as monitoring free drug concentration; analytical techniques for measuring concentrations of therapeutic drugs in biological fluids; the pre-analytical phase of drug testing; the effect of hemolysis, high bilirubin, lipemia, paraproteins, and system factors on therapeutic drug monitoring; interferences with measurement of anticonvulsants; pitfalls in measuring antidepressant drugs; immunosuppressive drugs; therapeutic monitoring in HIV/AIDS; pharmacogenomics and personalized medicine; interference of heterophilic
and other antibodies in measurement of therapeutic drugs by immunoassays; and drug-herb and drug-food interactions and their impact on drug monitoring.